pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Ofev
drug
save

Ofev

Marketedupdated 6mo ago
by Boehringer Ingelheim Corp
Approved
community read0 votes

🐶 often sniffed alongside

top 4
  • tagApproval10 co-mentions · 5 sources
  • drugnintedanib5 co-mentions · 5 sources
  • drugNINTEDANIB ESYLATE5 co-mentions · 5 sources
  • tagSmall Molecule5 co-mentions · 5 sources

indications

investigational
Pulmonary Fibrosis

all catalysts(4)

approval · 4
Apr 2, 2026
approval
8mo ago
NINTEDANIB ESYLATE — FDA approval
Ofev
→
Apr 2, 2026
approval
8mo ago
NINTEDANIB ESYLATE — FDA approval
Ofev
→
Apr 2, 2026
approval
8mo ago
NINTEDANIB ESYLATE — FDA approval
Ofev
→
Apr 2, 2026
approval
8mo ago
NINTEDANIB ESYLATE — FDA approval
Ofev
→

Trials studying Ofev

  • phase2A Multicenter, Randomized, Blinded, Placebo- and Active-Controlled Phase II Study to Evaluate the Efficacy and Safety of SYH9061 in Adult Patients With Idiopathic Pulmonary Fibrosisnot yet recruitingn=300
  • phase3A Study to Evaluate Long-term Safety of Nintedanib in Children and Adolescents With Interstitial Lung Disease (InPedILD®-ON)completedn=54
  • phase1Study to Determine Potential for Drug-drug Interactions When Co-administering Deupirfenidone (LYT-100) and Nintedanibcompletedn=24
  • —A Study Using a Disease Registry to Observe the Long-term Effects of Nintedanib in People With Scleroderma-related Lung Fibrosisactive not recruitingn=2,000
  • —NICEFIT-ON: A Study Under Routine Clinical Practice in Taiwan to Observe the Long-term Outcome of People With Certain Types of Lung Disease (PF-ILD, SSc-ILD, IPF) Who Start Treatment With Nintedanibcompletedn=214
  • —An Expanded Access Program to Provide Nintedanib to Patients With Non-IPF ILD Who Have no Alternative Treatment Possibilitiesapproved for marketing
  • phase1A Study in Healthy Men to Find the Best Formulation for Once Daily Intake of Nintedanibcompletedn=21
  • phase3Nintedanib for the Treatment of SARS-Cov-2 Induced Pulmonary Fibrosisrecruitingn=250

Patent cliff

source: FDA Orange Book
first barrier falls
Mar 6, 2027
106 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (16)

  • Dec 7, 2029patentUS 9907756*PED3.0y
  • Dec 7, 2029patentUS 9907756*PED3.0y
  • Dec 4, 2029patentUS 10105323*PED3.0y
  • Dec 4, 2029patentUS 10105323*PED3.0y
  • Jun 7, 2029formulationUS 99077562.5y
  • Jun 7, 2029formulationUS 99077562.5y
  • Jun 4, 2029formulationUS 101053232.5y
  • Jun 4, 2029formulationUS 101053232.5y
  • Jul 8, 2026patentUS 10154990*PED
  • Jul 8, 2026patentUS 10154990*PED
  • Apr 1, 2026patentUS 6762180*PED
  • Apr 1, 2026patentUS 6762180*PED
  • Jan 8, 2026method-of-use (U-2620)US 10154990
  • Jan 8, 2026method-of-use (U-2620)US 10154990
  • Oct 1, 2025compositionUS 6762180
  • Oct 1, 2025compositionUS 6762180

FDA exclusivities (4)

  • Mar 6, 2027PEDPediatric (6mo bonus)106d
  • Mar 6, 2027PEDPediatric (6mo bonus)106d
  • Sep 6, 2026ODE-261Orphan Drug (7y)
  • Sep 6, 2026ODE-261Orphan Drug (7y)

News(5)

  • Bristol Myers dips on ‘confounding’ lung drug results
    Only the lower of two tested doses of the idiopathic pulmonary fibrosis drug admilparant met the trial’s main objective, adding to analyst questions about the therapy’s prospects.
    biopharma_dive · 1mo ago
  • Endeavor’s threat to IPF incumbents increases after phase 2 win for Hedgehog inhibitor
    Endeavor BioMedicines solidified its potential threat to Big Pharma with a phase 2b readout suggesting its Hedgehog inhibitor could become the first drug to reduce lung fibrosis while increasing to…
    fiercebiotech · 1mo ago
  • BMS reports liver injury events in lung disease program, with key readout near
    Bristol Myers Squibb will soon release Phase 3 data for admilparant that could make or break Contineum Therapeutics’ rival product. But reports of a death due to liver injury in the pharma’s progra…
    biospace · 1mo ago
  • A PureTech startup banks $180M for a new IPF drug
    Celea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's Esbriet.
    biopharma_dive · 4mo ago
  • Avalyn, in pursuit of better lung drugs, banks $300M in an IPO
    The biotech will use the proceeds to develop inhalable versions of therapies already on the market for the “idiopathic” and “progressive” forms of pulmonary fibrosis.
    biopharma_dive · 6mo ago
brand
Ofev
generic
nintedanib esylate
indication
Systemic Sclerosis (Scleroderma)
phase
marketed
Data sources
openFDA · ClinicalTrials.gov
last refreshed 2h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?